CIRCLEGROW AGAR (POWDER)

Bacterial cell culture media Escherichia coli

Experiment
Bacterial cell culture media Escherichia coli
Product
CIRCLEGROW AGAR (POWDER) from MP Bio
Manufacturer
MP Bio

Protocol tips

Protocol tips
To prepare plasmids for DNA sequence analysis, the E. coli colony glycerol stocks that yielded positive recombinants according to the PCR colony screens were grown overnight at 37 °C in 2–3 ml of CircleGrow® broth (MP Biomedicals; Santa Ana, CA) in the presence of 50 μg/ml kanamycin.

Publication protocol

To prepare plasmids for DNA sequence analysis, the E. coli colony glycerol stocks that yielded positive recombinants according to the PCR colony screens were grown overnight at 37 °C in 2–3 ml of CircleGrow® broth (MP Biomedicals; Santa Ana, CA) in the presence of 50 μg/ml kanamycin.

Full paper   Login or join for free to view the full paper.

Reviews

CIRCLEGROW AGAR (POWDER) from MP Bio has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Bacterial cell culture media Escherichia coli using CIRCLEGROW AGAR (POWDER) from MP Bio.

View full paper   Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from MP Bio for CIRCLEGROW AGAR (POWDER) below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing Bacterial cell culture media Escherichia coli using CIRCLEGROW AGAR (POWDER) from MP Bio. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms